Pharmacokinetics and tissue distribution model of cabozantinib in rat determined by UPLC-MS/MS

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 983-984, Issue , 2015, Pages 125-131

  Wang, Xianqin ^a   Wang, Shuanghu ^b   Lin, Feiyan ^c   Zhang, Qingwei ^d   Chen, HuiLing ^e   Wang, Xianchuan ^a   Wen, Congcong ^a   Ma, Jianshe ^a   Hu, Lufeng ^c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b LISHUI PEOPLE S HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^d SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

^e WENZHOU UNIVERSITY   (China)

Author keywords

BP ANN; Cabozantinib; Pharmacokinetics; UPLC MS MS

Indexed keywords

AMINO ACIDS; BIOCHEMISTRY; HISTOLOGY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS; RATS; TISSUE;

BP-ANN; CABOZANTINIB; CONCENTRATION DISTRIBUTIONS; RECEPTOR TYROSINE KINASE; SMALL MOLECULE INHIBITOR; TISSUE DISTRIBUTIONS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (UPLC MS/MS); UPLC-MS/MS;

TISSUE ENGINEERING;

CABOZANTINIB; MIDAZOLAM; ANILIDE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL NEURAL NETWORK; BACK PROPAGATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG LIVER LEVEL; ELECTROSPRAY MASS SPECTROMETRY; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER; LUNG; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SIGNAL NOISE RATIO; SPLEEN; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; BLOOD; CALIBRATION; CHEMISTRY; DRUG STABILITY; METABOLISM; PROCEDURES; REPRODUCIBILITY; SPRAGUE DAWLEY RAT;

RATTUS;

ANILIDES; ANIMALS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; LIVER; MIDAZOLAM; NEURAL NETWORKS (COMPUTER); PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84921887704     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2015.01.020     Document Type: Article

References (19)

1. Atreya C.E., Song E.K., Messersmith W., Purkey A., Bagby S., Quackenbush K., Kelley R.K., Kwak E., Ryan D., Venook A., Arcaroli J.J. Potent antitumor activity of XL184 (cabozantinib), a c-MET and VEGFR2 inhibitor, in colorectal cancer patient-derived tumor explant models. Cancer Res. 2013, 73:LB-302.
2. Hart C.D., De Boer R.H. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. Oncotargets Ther. 2013, 6:1-7.
3. Aftab D., Schimoller F., Zayzafoon M., Chung L., Zhau H., Fagerlund K. Mechanistic studies of cabozantinib, a Met-Vegfr2 inhibitor with anti-tumor activity in soft tissue and bone. Ann. Oncol. 2012, 23:20.
4. Yakes F.M., Chen J., Tan J., Yamaguchi K., Shi Y.C., Yu P.W., Qian F., Chu F.L., Bentzien F., Cancilla B., Orf J., You A., Laird A.D., Engst S., Lee L., Lesch J., Chou Y.C., Joly A.H. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 2011, 10:2298-2308.
5. Vaishampayan U. Cabozantinib as a novel therapy for renal cell carcinoma. Curr. Oncol. Rep. 2013, 15:76-82.
6. Pinto A. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma. Cancer Chemother. Pharmacol. 2014, 73:219-222.
7. Bentzien F., Zuzow M., Heald N., Gibson A., Shi Y.C., Goon L., Yu P.W., Engst S., Zhang W.T., Huang D.H., Zhao L.R., Vysotskaia V., Chu F., Bautista R., Cancilla B., Lamb P., Joly A.H., Yakes F.M. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid 2013, 23:1569-1577.
8. Xiang Q.F., Chen W.Q., Ren M., Wang J.N., Zhang H.W., Deng D.Y.B., Zhang L., Shang C.Z., Chen Y.J. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin. Cancer Res. 2014, 20:2959-2970.
9. Kurzrock R., Sherman S.I., Ball D.W., Forastiere A.A., Cohen R.B., Mehra R., Pfister D.G., Cohen E.E.W., Janisch L., Nauling F., Hong D.S., Ng C.S., Ye L., Gagel R.F., Frye J., Muller T., Ratain M.J., Salgia R. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 2011, 29:2660-2666.
10. Smith D.C., Smith M.R., Sweeney C., Elfiky A.A., Logothetis C., Corn P.G., Vogelzang N.J., Small E.J., Harzstark A.L., Gordon M.S., Vaishampayan U.N., Haas N.B., Spira A.I., Lara P.N., Lin C.C., Srinivas S., Sella A., Schoffski P., Scheffold C., Weitzman A.L., Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J. Clin. Oncol. 2013, 31:412-419.
11. Liu K., Zhong D.F., Chen X.Y. Enantioselective determination of doxazosin in human plasma by liquid chromatography-tandem mass spectrometry using ovomucoid chiral stationary phase. J. Chromatogr. B 2010, 878:2415-2420.
12. Cai J., Lin C., Ma J., Hu L., Lin G., Wang X. Development of LC-MS determination method and back-propagation ANN pharmacokinetic model of corynoxeine in rat. J. Chromatogr. Sci. 2014, 52:661-665.
13. Dutta M., Basu J.K. Application of artificial neural network for prediction of Pb(II) adsorption characteristics. Environ. Sci. Pollut. Res. Int. 2013, 20:3322-3330.
14. Abdul Rahman M.B., Chaibakhsh N., Basri M., Salleh A.B., Abdul Rahman R.N. Application of artificial neural network for yield prediction of lipase-catalyzed synthesis of dioctyl adipate. Appl. Biochem. Biotechnol. 2009, 158:722-735.
15. Tan M., Pu J., Zheng B. Optimization of breast mass classification using sequential forward floating selection (SFFS) and a support vector machine (SVM) model. Int. J. Comput. Assist. Radiol. Surg. 2014, 9(6):1005-1020.
16. Cao J., Xiong L. Protein sequence classification with improved extreme learning machine algorithms. BioMed Res. Int. 2014, 2014:103054.
17. Zhao X., Xu K., Shi H., Cheng J., Ma J., Gao Y., Li Q., Ye X., Lu Y., Yu X., Du J., Du W., Ye Q., Zhou L. Application of the back-error propagation artificial neural network (BPANN) on genetic variants in the PPAR-gamma and RXR-alpha gene and risk of metabolic syndrome in a Chinese Han population. J. Biomed. Res. 2014, 28:114-122.
18. Ding H., Lu Q., Gao H., Peng Z. Non-invasive prediction of hemoglobin levels by principal component and back propagation artificial neural network. Biomed. Opt. Express 2014, 5:1145-1152.
19. Yamamura S., Kawada K., Takehira R., Nishizawa K., Katayama S., Hirano M., Momose Y. Artificial neural network modeling to predict the plasma concentration of aminoglycosides in burn patients. Biomed. Pharmacother. 2004, 58:239-244.